Document Classification

Section Type: RESULTS

Text: The most common grade 3 or 4 adverse events were low neutrophil count (15 [11 %] preoperatively in the chemotherapy alone group vs six [4 %] in the chemotherapy plus cetuximab group ; four [4 %] vs eight [8 %] postoperatively), embolic events (six [4 %] vs eight [6 %] preoperatively ; two [2 %] vs three [3 %] postoperatively), peripheral neuropathy (six [4 %] vs one [1 %] preoperatively ; two [2 %] vs four [4 %] postoperatively), nausea or vomiting (four [3 %] vs six [4 %] preoperatively ; four [4 %] vs two [2 %] postoperatively), and skin rash (two [1 %] vs 21 [15 %] preoperatively ; 0 vs eight [8 %] postoperatively).